Neuroendocrine Carcinoma Treatment Market – Business Opportunities and Global Forecast to 2029

The market for treating neuroendocrine carcinomas was estimated at US$ 1.3 billion in 2018 and is anticipated to grow at a CAGR of 7% over the following five years (2019 – 2029).

Data Points Market Insights
Market Value 2022 USD 1.7 Bn
Market Value 2029 USD 2.9 Bn
CAGR 2022-2029 8.0%
Key Players The key players are Pfizer Inc., Novartis AG, Chiasma Inc., Ipsen, Abbvie Inc., Valeant Pharmaceuticals International Inc., Jubilant Life Sciences Ltd., Teva Pharmaceutical Industries Ltd, F. Hoffmann-La Roche Ltd, Advanced Accelerator Applications, Mateon Therapeutics, Inc., Lexicon Pharmaceuticals, Inc., Isotopen Technologien München AGGlobal, Hutchison China MediTech Ltd, Amgen Inc, Celgene Corporation
Share of Top 5 Countries 54.2%

Request a report sample to gain comprehensive insights at@

The market is expected to have exceptional growth over the course of the forecast period, driven mostly by collaborative tactics for quick drug research for the treatment of neuroendocrine carcinoma. The market for treating neuroendocrine carcinoma is anticipated to grow at a faster rate than average during the forecast period due to factors including an increase in the number of patients being diagnosed with the disease, an increase in the number of patients seeking treatment, and innovative drugs undergoing clinical trials. The overall survival rate for patients with neuroendocrine carcinoma increased to 73.1% at two years and 44.2% at four years when Progenics Pharmaceuticals revealed long-term follow-up results from their pivotal phase 2 study of Azdera in June 2019.

Key Takeaways of Neuroendocrine Carcinoma Treatment Market Study

  • Owing to large patient pool seeking treatment for gastric neuroendocrine tumors, the segment is expected to dominate the neuroendocrine carcinoma treatment market.
  • Somatostatin analog therapy for vasoactive intestinal peptide, carcinoid tumors, pituitary adenomas, and other indications is expected to gain traction over targeted therapy and chemotherapy during the forecast period.
  • Hospitals remain prominent end users as compared to clinics, as hospitalization of patients is required to monitor the progress of therapy deployed during the treatment of neuroendocrine carcinoma.
  • North America is expected dominate the global neuroendocrine carcinoma treatment market, owing to improved healthcare infrastructure, favorable reimbursement scenario, increasing research grants, and large target patient pool.

For any Queries Related to the Report, Ask an Analyst@

Neuroendocrine Carcinoma Drug Manufacturers Focusing on Collaborations to Gain Competitive Advantage

AbbVie Inc., Advanced Accelerator Applications, and F. Hoffmann-La Roche are among the leading manufacturers that operate in the neuroendocrine carcinoma treatment market. In December 2019, AbbVie and Scripps Research announced a collaboration to develop a broad range of new therapeutics in the areas of oncology, immunology, neurology, and fibrosis. This strategic move is expected to cater to the needs of patients by innovating refined novel medicines. Eisai’s Levinima was approved in combination with Novartis’s Afinitor for the treatment of advanced renal cell carcinoma, in May 2016. This collaboration agreement has set the terms, whereby the sales teams from both pharmaceutical companies will promote the availability of this combination regimen to health service providers. In November 2017, VBL Therapeutics and NanoCarrier Co., Ltd. signed an exclusive agreement for VB-111 for the development, commercialization, and supply of ofranergene obadenovec (VB-111) in Japan. In December 2018, Advanced Accelerator Applications entered into an exclusive option and license agreement with FUJIFILM Toyama Chemical Co. to develop and commercialize radiolabeled molecules for oncology indications.

Neuroendocrine Carcinoma Treatment Market by Category

By Indication:

  • Gastric Neuroendocrine Tumors
  • Lung Neuroendocrine Tumors
  • Pancreatic Neuroendocrine Tumors
  • Appendicular Neuroendocrine Tumors

By Treatment Type:

  • Somatostatin Analogs
  • Targeted Therapy
    • Tyrosine Kinase Inhibitors
    • mTOR Inhibitors
  • Chemotherapy
    • Antimetabolites
    • Alkylating Agents
    • Natural Products

By End User:

  • Hospitals
  • Clinics
  • Oncology Centers
  • Ambulatory Surgery Centers

By Region:

  • North America
  • Latin America
  • Western Europe
  • Eastern Europe
  • APEJ
  • Japan
  • Middle-East & Africa

We Offer tailor-made Solutions to fit Your Requirements, Request Customization @

More Valuable Insights on Neuroendocrine Carcinoma Treatment Market

Neuroendocrine carcinoma treatment market, a new study from Future Market Insights, provides unparalleled insights on the evolution of the market during 2014–2018, and presents demand projections for 2019–2029, on the basis of disease indication (gastric neuroendocrine tumors, lung neuroendocrine tumors, pancreatic neuroendocrine tumors, and appendiceal neuroendocrine tumors), treatment type (somatostatin analogs, targeted therapy, and chemotherapy), end user (hospitals, clinics, oncology centers, and ambulatory surgical centers), across seven major regions.

About FMI                     

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.


Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries:
Browse latest Market Reports:
LinkedIn| Twitter| Blogs 

About the Author

Leave a Reply

Your email address will not be published. Required fields are marked *

You may also like these